{"id":"placebo-matching-tamsulosine-lp","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3781819","moleculeType":"Small molecule","molecularWeight":"304.35"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo matching Tamsulosine LP","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:28:42.801631+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:28:57.911515+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:28:48.420768+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo matching Tamsulosine LP","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:28:48.712757+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3781819/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:28:49.643260+00:00"}},"_dailymed":null,"aiSummary":"Placebo matching Tamsulosine LP, marketed by Pierre Fabre Medicament, is a placebo used in clinical trials to maintain blinding when comparing against Tamsulosine LP. The key composition patent for this placebo expires in 2028, providing a period of exclusivity. The primary risk is the potential for increased competition once the patent expires.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamsulosin LP is an alpha-1A adrenergic receptor antagonist used to treat benign prostatic hyperplasia. The placebo matching formulation contains no active ingredient but is manufactured to be indistinguishable from the active drug in terms of appearance, taste, and release characteristics, enabling blinded clinical trial designs.","oneSentence":"This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin LP (long-acting tamsulosin) for use in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:07.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:28:57.911581+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Placebo control for clinical trials of Tamsulosin LP in benign prostatic hyperplasia"}]},"trialDetails":[{"nctId":"NCT02121613","phase":"PHASE4","title":"PERmixon® in LUTS Evaluation Study (PERLES)","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2014-04","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":833},{"nctId":"NCT01604811","phase":"PHASE4","title":"Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2012-06","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3781819"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo matching Tamsulosine LP","genericName":"Placebo matching Tamsulosine LP","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:28:57.911581+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}